The 340B Drug Pricing Program continues to expand far more quickly than the overall pharmaceutical market—and some channels are benefiting more than others.
As you will see below, mail and specialty pharmacies’ purchases of products that are eligible for 340B discounts have grown by an incredible 56% per year since 2017. That’s about six times faster than the overall mail and specialty market.
Consequently, specialty pharmacies have gained a greater share of the 340B market. Businesses owned by a few multi-billion-dollar, for-profit, publicly traded companies—Cigna, CVS Health, and UnitedHealthcare—are the primary beneficiaries of this astonishing growth.
To help you make sense of the market changes, I have also included a brief video to explain 340B’s growth and the expansion of contract pharmacies. The video is excerpted from my recent Drug Channels Update: 340B Controversies and Outlook video webinar.
Grab some popcorn and enjoy the show!
Read more »
Source: Post feed
